[IMS-TH-02] Morning Seminar 2: The Leading Edge of Regenerative Medicine: What Will Happen Over the Next Decade?
- Apr 03 (Thu)
- 07:30 - 08:30
- Room 6 - Tokyo International Forum 5F Hall D5
- Otsuka Pharmaceutical Co.,Ltd.
- Cornea, Conjunctiva
- Chair）Shigeru Kinoshita、Chair）Masayo Takahashi
- Tissue-engineering therapies aimed at treating various ophthalmology-related diseases have been anxiously anticipated. In this seminar, attendees will be provided with the latest information regarding recent advancements in regenerative medicine-based technology for the treatment of devastating ocular disorders, and tissue-engineering therapies for corneal epithelial and endothelial stem-cell dysfunction will be addressed. In addition, attendees will be introduced to a scheduled pilot study of induced pluripotent stem-cell-derived retinal pigment epithelium cell-sheet transplantation for the treatment of age-related macular degeneration. These important topics will help illustrate the latest knowledge and cutting-edge ideas towards future therapeutic modalities for the treatment of devastating ophthalmology-related diseases.